We found no evidence of differences between the ASN and SSN groups in terms ofage (P = .778), lymph node involvement (P =.068), or EGFR mutation status (P = .293).Compared with patients with SSNs, patients with ASNs were more likely to smoke(16 of 48 [33.3%] vs 20 of 121 [16.5%]; P = .016) and havenonsmall adenocarcinoma (47 of 49 [95.9%] vs 74 of 123 [60.2%];P < .001) and advanced-stage adenocarcinoma (27 of47 [57.4%] vs 40 of 120 [33.3%]; P = .004). This evidence concerns the gene EGFR and adenocarcinoma.